A Double-Blind, Placebo-Controlled, Randomized, Multicenter, Proof of Concept and Dose-Finding Phase II Clinical Trial to Investigate the Safety, Tolerability and Efficacy of ADRECIZUMAB in Patients With Septic Shock and Elevated Adrenomedullin

Trial Profile

A Double-Blind, Placebo-Controlled, Randomized, Multicenter, Proof of Concept and Dose-Finding Phase II Clinical Trial to Investigate the Safety, Tolerability and Efficacy of ADRECIZUMAB in Patients With Septic Shock and Elevated Adrenomedullin

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Adrecizumab (Primary)
  • Indications Septic shock
  • Focus Adverse reactions; Proof of concept
  • Acronyms AdrenOSS-2
  • Sponsors Adrenomed
  • Most Recent Events

    • 11 Aug 2017 According to an Adrenomed AG media release, the company has received the favorable opinion of the Central Ethics Committee of the University of Aachen to start this trial. Patient enrollment in Germany expected to start by September; study approvals expected soon in Belgium, France and the Netherlands.
    • 15 Mar 2017 Status changed from planning to not yet recruiting.
    • 21 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top